Tandem Diabetes Care competitors

Kevin Sayer is the Executive Chairman of the board of directors, President and Chief Executive Officer of Dexcom. He joined Dexcom as President and Chief Operating Officer in 2011. In this executive role, Kevin was responsible for research and development, manufacturing, clinical, regulatory, finance, sales and marketing functions. During his tenure with Dexcom, he has been instrumental in leading the development of new technology, including the Dexcom G5 Mobile CGM System, the Dexcom G4 PLATINUM System with Share and several other product launches in the US and Europe. Prior to joining Dexcom, Kevin served as Chief Financial Officer of Biosensors International, a medical technology company focused on the development, manufacturing and commercialization of medical devices used in interventional cardiology and critical care procedures. Kevin also served as CFO of MiniMed, Inc. from 1994 until its acquisition by Medtronic, Inc. in 2001. Kevin received his master's and bachelor’s degrees in Accounting and Information Systems from Brigham Young University.

Mr. Michael Klein serves as the Chairman and CEO for iCAD Medical (Nasdaq: ICAD), a clinical artificial intelligence company focused on the detection of breast cancer and other proliferative diseases. iCAD's, therapy subsidiary, Xoft Inc. uses novel electronic brachytherapy for the treatment of breast and gynecological cancers as well as brain, rectal and prostate cancers. Between December 2014 and October 2018, when he assumed the above position, Mr. Klein served as Chief Executive Officer at Inflection Point Consulting, an executive coaching and consulting firm with a focus on medical technology, biopharma and healthcare services. During this same time period, Mr. Klein served as a Adjunct Professor at the Leavey School of Business at Santa Clara University. Prior to that, from December 2011 to November 2014. Klein was the Chief Executive Officer at SonaCare Medical, LLC (f/k/a US HIFU, LLC), a global leader in minimally invasive high intensity focused ultrasound technologies used for the treatment of prostate and other urological cancers. From April 2011 to December 2011, Mr. Klein was the President of the Civco Radiation Oncology Division within Roper Industries, a diversified industrial company that produces engineered products for global niche markets. He was President and Chief Executive Officer of Xoft, Inc., a medical device company, a position he held from December 2004 until the sale of Xoft to iCAD Medical in December 2010. Prior to joining Xoft, from 2000 to 2004, Mr. Klein served as Chairman, President and Chief Executive Officer of R2 Technology, Inc., a breast and lung cancer computer aided detection company. The first company to bring a medical artificial intelligence technology before the FDA and receive PMA Regulatory Approval. Previously, Mr. Klein served in VP, Sales and Marketing roles at Varian Medical Systems (VAR) and Becton Dickinson (BDX). Mr. Klein received a Bachelor of Arts degree from the University at Albany, SUNY. Mr. Klein also received his M.B.A. from the New York Institute of Technology and completed his post-graduate Executive Education Studies at Harvard University and Babson College. Mr. Klein lives in Mountain View, California with his wife and 3 children, in close proximity. Mr. Klein splits time between iCAD headquarters in Nashau, NH and Xoft’s headquarters in San Jose, CA.

Scott Flora has more than 40 years of healthcare experience in surgical devices and is currently serving as Board Chair for Palliare Ltd and New View Surgical. He is also on the Board of Conventus/Flower Orthopaedics. Prior to that Scott held the following leadership roles, Interim President and CEO of Invuity, Executive Director of Conventus Orthopaedics, President and CEO of OmniGuide Surgical, President of Covidien's Surgical Device Group ,President Smith& Nephew Orthopedic Reconstruction, General Manager Smith&Nephew Trauma , Sr. V.P. Sales US and Europe, Global V.P. Sales & Marketing Ioptex Research. Scott has also served on three public company boards, Invuity, MAKO Surgical and Tengion. Scotts skills have been demonstrated in:Building Effective TeamsInnovation ManagementResults OrientedStrategic AgilityBuilding a Strong Vision supported by ValuesGlobal LeadershipCommercial ExecutionGovernance

Tyler has more than two decades of experience with McKesson, having served in a wide variety of leadership roles throughout the company. He has led nearly every major business within the company as well as McKesson’s corporate strategy and business development unit.

Chris Barry serves as the chief executive officer and a member of the NuVasive Board of Directors. Prior to this role, Mr. Barry served as senior vice president and president of surgical innovations, the second largest business unit at Medtronic with $5.5 billion in annual revenue, from 2015 to 2018. In this role, Chris provided strategic direction to more than 14,000 employees working in 78 countries, including 10 manufacturing sites and multiple R&D centers. Prior to the acquisition of Covidien by Medtronic, Mr. Barry was president, Advanced Surgical Technologies of Covidien, where he led global strategy, product portfolio and U.S. commercial teams for the $3.2 billion global business unit. Mr. Barry spent more than 15 years in increasing commercial and executive leadership roles at Covidien. Mr. Barry received a bachelor’s degree in environmental science from Texas Tech University.

Kevin serves as the fifth Chairman and CEO at Stryker since it was founded in 1941 by Dr. Homer Stryker, an orthopaedic surgeon. Stryker is a leading medical technology company with over 40,000 employees. Kevin was born in India, grew up in Canada, and has lived and worked in four countries and four industries. He is the current chair of AdvaMed (Med-Tech trade association) and is a member of the Business Roundtable and Business Council. He is also active with community boards.

Joined Varian as an intern in 1999, then full time in 2001, and has held multiple cross-functional roles and executive positions during two-decade tenure with the company. Intimate understanding of healthcare, software solutions, medical devices, technology trends, reimbursement trends and strategies that lead to success in targeted channel segments globally. Marketing strategy, new product launch, portfolio strategy, M&A, P&L, restructuring, government relations, and general management experience. Consistent creation of strategies and execution against operating plans, sales goals and market objectives, including extensive experience of both high growth and slow growth periods (turnaround plans) of Varian Medical Systems journey from $500M to over $3B. Including returning Varian to double digit growth following becoming President of the $3B+ P&L of Oncology systems. Strong leadership skills with a track record of creating an inspiring vision and communicating effectively both internally/externally through developing cultural, servant leadership and focusing on people/teams to drive net promoter scores to all-time highs and enable sustainable long-term success.